Summary
The pharmacokinetics of 2-mercaptopropionylglycine (2-MPG) was studied in ten healthy volunteers after a single i. v. injection of 250 mg (1532 μmol).
The total and non-protein-bound concentrations versus time curves were best described by a three-exponential function with terminal half-lives of 55 and 59 h respectively. Body clearance based upon the total concentration was estimated to be 105 and 231 ml/min based on the non-protein-bound 2-MPG. The corresponding values for Vss were 99 l and Vss,n 173 l, and for Vγ485 l and Vγ,n 1121 l respectively. 75% of the dose was excreted in the urine, mainly during the first 6 h after injection. The proportion of non-protein-bound 2-MPG diminished exponentially during the first 15 h and then levelled off at about 30%.
There was a nonlinear increase in the non-protein-bound fraction of 2-MPG as the total plasma concentration of the drug increased.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Crawhall JC, Scowen EF, Watts R (1963) Effect of pencillamine on cystinuria. Br Med J 1: 588–590
Halperin EC, Thier SO, Rosenberg LE (1981) The use of D-pencillamine in cystinuria: Efficacy and untoward reactions. Yale J Biol Med 54: 439–446
Jaffe J (1986) Adverse effects profile of sulphydryl compounds in man. Am J Med 80: 471–476
Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV (1986) Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol 136: 1003–1008
Remien A, Kallistratos G, Burchardt P (1975) Treatment of cystinuria with Thiola (α-mercaptopropionylglycine). Eur Urol 1: 227–228
Linari F, Marangella M, Fruttero B, Bruno M (1980) The natural history of cystinuria: a 15 year follow-up in 106 patients. Urolithiasis, p 145, Plummer Press, NY
Hautmann R (1983) Cystine-stone therapy with alpha-mercaptopropionylglycine. Wld J Urol 1: 186–191
Denneberg T, Jeppsson J-O, Stenberg P (1983) Alternative treatment of cystinuria with alpha-mercaptopropionylglycine, Thiola. Proc Eur Dial Transplant Assoc 20: 427–432
K»gedal B, Carlsson M, Denneberg T (1986) Determination of 2-mercaptopropionylglycine in plasma and urine by high performance liquid chromatography. J Chromatogr 380: 301–311
K»gedal B, Andersson T, Carlsson M, Denneberg T (1987) High-performance liquid chromatography of 2-mercaptopropionic acid in plasma and urine after treatment with thiopronine. J Chromatogr 417: 261–267
Gibaldi M, McNamara PJ (1978) Apparent volumes of distribution and drug binding to plasma proteins and tissues. Eur J Clin Pharmacol 13: 373–378
Metzler CM, Elfing GL, McEwen AJ (1974) A package of computer programs for pharmacokinetic modeling. Biometrics 30: 562–563
Wilkinson GR, Shand DG (1975) A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 10: 377–390
Jusko WJ, Gibaldi M (1972) Effects of change in elimination on various parameters of the two-compartment open model. J Pharm Sci 61: 1270–1273
Colburn WA, Schentag JJ, Jusko WJ, Gibaldi M (1978) A model for the prospective identification of the prenephrotoxic state during gentamycin therapy. J Pharmacokinet Biopharm 6: 179–186
Kallistratos G (1977) Synthese neuer potentieller L-Cystin lösender Verbindungen. Fortschr Urol Nephrol 9: 324–334
Duchin KL, Singhvi SM, Willard DA, Migdalof BH, McKinstry DN (1982) Captopril kinetics. Clin Pharmacol Ther 31: 452–458
Netter P, Bannwarth B, Péré P, Nicolas A (1987) Clinical Pharmacokinetics of D-Penicillamine. Clin Pharmacokinet 13: 317–333
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlsson, S.M., Denneberg, T., Emanuelsson, B.M. et al. Pharmacokinetics of intravenous 2-mercaptopropionylglycine in man. Eur J Clin Pharmacol 38, 499–503 (1990). https://doi.org/10.1007/BF02336691
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02336691